MEMBERSHIP

September 26, 2025

For Immediate Release

Company name: VITAL KSK HOLDINGS, INC.
Representative: Taisuke Murai, President & CEO
Company address: 1-1-12, Tsurumaki, Setagaya-ku, Tokyo
(Securities Code: 3151, TSE Prime Market)
Contact: Kenta Sato, Executive Officer,
Manager of Corporate Planning Department
(Tel. +81-3-5787-8565)

Disclosure of Subsidiary Company Name

VITAL KSK HOLDINGS, INC. (hereinafter "the Company") had not disclosed the trade name (company name) of the subsidiary in the "Notice Regarding Establishment of Subsidiary" dated August 29, 2025, due to trademark application matters. We are now able to disclose this information.

1. Overview of the Subsidiary (Including Previously Disclosed Information)
*Newly disclosed information is underlined

Company Name	<u>MEDLEAP PHARMA COMPANY LIMITED</u>
Representative and Officers	President and Representative Director: Yuichi Kobayashi Director: Taisuke Murai Director: Takeshi Ichijo Director: Toshiyuki Iguchi Director: Mitsunao Suzuki Director: Hiroshi Yokoyama Auditor: Isao Kita
Establishment	<u>September 16, 2025</u>
Head Office Location	<u>3-3-1 Yaotome, Izumi-ku, Sendai, Miyagi</u>
Capital	100 million yen
Shareholder Composition	Vital KSK Holdings, Inc. 100%
Fiscal Year End	March 31
Business Description	Research, development, manufacturing, and sales of pharmaceuticals

Relationship between the Company and the Subsidiary	Capital Relationship	The subsidiary is 100% owned by the Company.
	Personnel Relationship	Yuichi Kobayashi, who will serve as Representative Director, is an Executive Officer of the Company. Additionally, officers of the Company are scheduled to serve concurrently as directors and auditors of the subsidiary. Furthermore, employees of the Company group are scheduled to hold concurrent positions in the subsidiary.
	Business Relationship	Not applicable as this is a newly established company.

2. Future Outlook

The impact of the establishment of this subsidiary on the consolidated financial results for the fiscal year ending March 2026 is expected to be minimal.

The Company will promptly disclose any matters that should be announced as they become clear.